{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T16:48:17Z","timestamp":1769100497790,"version":"3.49.0"},"reference-count":21,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2007,2,7]],"date-time":"2007-02-07T00:00:00Z","timestamp":1170806400000},"content-version":"vor","delay-in-days":37,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Exper Ophthalmology"],"published-print":{"date-parts":[[2007,1]]},"abstract":"<jats:title>A<jats:sc>bstract<\/jats:sc><\/jats:title><jats:p><jats:bold>Purpose:\u2002<\/jats:bold> \u2002To assess the efficacy and safety of photodynamic therapy (PDT) for choroidal neovascularization (CNV) secondary to age\u2010related macular degeneration (AMD) and other conditions by analysing visual acuity changes.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> \u2002A retrospective review of patients treated with PDT was conducted. CNV was confirmed on fluorescein angiography. Visual acuity outcomes were recorded at 3\u2010monthly intervals to a maximum of 48\u2003months. The primary outcome measure was the proportion of patients avoiding moderate visual loss (losing less than three lines of visual acuity relative to baseline) at 12\u2003months.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> \u2002A total of 343 patients receiving PDT were followed up for a mean of 14.9\u2003months. Two hundred and eighty\u2010five (83%) patients presented with CNV due to AMD and 58 patients (17%) due to other causes. Seventy per cent of patients with CNV secondary to AMD avoided moderate visual loss at both 12 and 24\u2003months. Secondary outcomes (including mean change in visual acuity, proportion of patients with stable or improved vision and proportion of patients with severe vision loss) also compared favourably with the Treatment of Age\u2010Related Macular Degeneration with Photodynamic Therapy (TAP) Investigation. Of patients with CNV secondary to causes other than AMD, 76% avoided moderate visual loss at both 12 and 24\u2003months. The safety profile identified one severe adverse reaction, with development of a serous pigment epithelial detachment and subsequent rip.<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold> \u2002The results of this present retrospective, open\u2010label, clinical practice study in New Zealand are consistent with the findings of multicentre randomized, placebo\u2010controlled trials and confirm the treatment benefit of PDT in a clinical setting.<\/jats:p>","DOI":"10.1111\/j.1442-9071.2007.01394.x","type":"journal-article","created":{"date-parts":[[2007,2,7]],"date-time":"2007-02-07T10:42:35Z","timestamp":1170844955000},"page":"24-31","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Photodynamic therapy with verteporfin for choroidal neovascularization due to age\u2010related macular degeneration and other causes: a New Zealand outcomes study"],"prefix":"10.1111","volume":"35","author":[{"given":"Dianne M","family":"Sharp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susannah","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline M","family":"Markey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,2,7]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.122.4.564"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.116.4.514"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.117.10.1329"},{"key":"e_1_2_6_5_2","first-page":"198","article-title":"Photodynamic therapy of subfoveal choroidal neovascularization in age\u2010related macular degeneration with verteporfin: two\u2010year results of 2 randomized clinical trials \u2013 TAP report 2","volume":"119","author":"Treatment of Age\u2010Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group.","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.120.10.1307"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.123.9.1283"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(01)00544-9"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(01)00967-9"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(02)01998-X"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.123.4.448"},{"key":"e_1_2_6_12_2","volume-title":"How to Use the Evidence: Assessment and Application of Scientific Evidence.","author":"National Health and Medical Research Council.","year":"2000"},{"key":"e_1_2_6_13_2","first-page":"239","article-title":"Photodynamic therapy in age\u2010related macular degeneration \u2013 results of one year observation","volume":"104","author":"Wykrota H","year":"2002","journal-title":"Klin Oczna"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2003.08.009"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6701329"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1159\/000076843"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-200410000-00013"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.122.6.853"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-004-1071-z"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-200502000-00002"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(03)00223-X"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2005.02.011"}],"container-title":["Clinical &amp; Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1442-9071.2007.01394.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1442-9071.2007.01394.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T06:12:37Z","timestamp":1696918357000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1442-9071.2007.01394.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["10.1111\/j.1442-9071.2007.01394.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1442-9071.2007.01394.x","archive":["Portico"],"relation":{},"ISSN":["1442-6404","1442-9071"],"issn-type":[{"value":"1442-6404","type":"print"},{"value":"1442-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1]]},"assertion":[{"value":"2007-02-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}